Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Chen, Y. H.; Park, J. W.; Blanc, J. F.; Bolondi, L.; Klumpen, H. J.; Chan, S. L.; Dadduzio, V.; Hessel, C.; Borgman-Hagey, A. E.; Schwab, G.; Kelley, R. K. |
| Abstract Title: | Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 206s |
| Language: | English |
| ACCESSION: | WOS:000442916001596 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4019 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4019 -- Source: Wos |
